Video

Findings help investigators understand how FDA-approved AGN-19058 behaves

Author(s):

Kassi Filkins
Conferences|ASCRS

George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Related Content
Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy
May 20th 2025

Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/peshkova)
May 17th 2025

Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
May 16th 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

Q&A: Anat Loewenstein, MD, and results of a consensus group on managing diabetic retinopathy
May 16th 2025

Q&A: Anat Loewenstein, MD, and results of a consensus group on managing diabetic retinopathy

© 2025 MJH Life Sciences

All rights reserved.